We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
By Adria Calatayud
Novartis said its Scemblix drug met its primary goals in a late-stage clinical trial for newly diagnosed patients with chronic myeloid leukemia.
The Swiss pharmaceutical company said Monday that Scemblix showed superior major molecular response compared to approved standard-of-care treatments that known as tyrosine kinase inhibitors--a type of targeted therapy--at week 48 of treatment.
Scemblix also demonstrated a favorable safety and tolerability profile with fewer adverse events and treatment discontinuations relative to the standard of care, Novartis said.
The company said the trial continues and that it will release new data evaluating patients' major molecular response after 96 weeks of treatment, the key secondary goal of the trial, as well as other secondary objectives.
Details will be presented at an upcoming medical conference and included as part of regulatory submissions in 2024, Novartis said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 08, 2024 01:46 ET (06:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions